Drug details

Piqray (alpelisib tablets)

type of Antineoplastics PI3K Inhibitors

Piqray (alpelisib) is a kinase inhibitor indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.

This drug may have the following side effects:

• hives,
• difficulty breathing,
• swelling of your face, lips, tongue, or throat,
• fever,
• pale skin,
• cold hands and feet,
• confusion,
• fast heartbeats,
• chest pain,
• dry mouth,
• cough,
• trouble swallowing,
• unusual tiredness,
• sore throat,
• burning eyes,
• skin pain,
• red or purple skin rash with blistering and peeling,
• little or no urination,
• increased thirst,
• increased urination,
• fruity breath odor,
• red or swollen gums,
• weight loss
• severe or ongoing diarrhea,
• blisters or ulcers in your mouth,
• hunger, and
• shortness breath,

The following drugs are related to Piqray, either as a replacement or used together:

• Verzenio (abemaciclib tablets)
• Vijoice (alpelisib tablets)
• Arimidex (anastrozole)
• Aredia (pamidronate disodium)
• Aromasin (exemestane)
• Fareston (toremifene)
• Faslodex (fulvestrant)
• Lynparza (olaparib capsules for oral administration)
• Nerlynx (neratinib tablets)
• Perjeta (pertuzumab)
• Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf injection)
• Talzenna (talazoparib capsules)
• Tukysa (tucatinib tablets)